Mantle Cell Lymphoma

James N. Gerson, MD, discusses recent updates in relapsed/refractory mantle cell lymphoma.

During a recent OncLive Peer Exchange, a panel of leukemia and lymphoma experts discussed emerging BTK inhibitors.

Andre Goy, MD, MS, discusses treatment approaches for older patients with mantle cell lymphoma.

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the FDA approval of zanubrutinib (Brukinsa) in mantle cell lymphoma (MCL).

The FDA has granted an accelerated approval to zanubrutinib capsules for the treatment of adult patients with mantle cell lymphoma who have received ≥1 prior therapy.

Simon Rule, MD, PhD, discusses what the treatment landscape of mantle cell lymphoma may look like in the next decade.

The phase I/II CIRLL study, which is evaluating the combination of the monoclonal antibody cirmtuzumab (UC-961) plus ibrutinib has opened an expansion cohort to include patients with mantle cell lymphoma.

Jia Ruan, MD, PhD, hematologist/oncologist, Weil Cornell Medicine, examined the evolving treatment landscape for mantle cell lymphoma, with an emphasis on BTK inhibitors.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the addition of acalabrutinib (Calquence) to bendamustine and rituximab (Rituxan; BR) in mantle cell lymphoma (MCL).

Andrew D. Zelenetz, MD, PhD, discusses research with zanubrutinib in mantle cell lymphoma.

James N. Gerson, MD, assistant professor of clinical medicine, Perelman School of Medicine, University of Pennsylvania, discusses strategies aimed at alleviating toxicity in older patients with mantle cell lymphoma (MCL).

James N. Gerson, MD, discusses exciting updates in mantle cell lymphoma and chronic lymphocytic leukemia and other potentially practice-changing trials on the horizon.

Ezzat Elhassadi, MD, discusses the results from a 10-year institutional analysis and how the presence of a TP53 mutation can correlate with survival outcomes in patients with mantle cell lymphoma.

Michael Wang, MD, discusses the toxicity profiles of the BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma.

Simon Rule, MD, discusses the standard of care for MCL treatment and future regimens that could transform clinical practice.

James N. Gerson, MD, discusses the watch-and-wait approach for patients with mantle cell lymphoma.

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the future therapeutic landscape of mantle cell lymphoma.

Michael Wang, MD, discusses data from a phase I/II study looking at the use a triplet regimen of vorinostat, cladribine, and rituximab in patients with newly diagnosed mantle cell lymphoma.

Andrew D. Zelenetz, MD, PhD, discusses approved treatment options for patients with mantle cell lymphoma, as well as treatments coming down the pipeline.

Andrew D. Zelenetz, MD, PhD, discusses the use of emerging targeted therapies in mantle cell lymphoma.

Andre Goy, MD, MS, discusses cutting-edge CAR T-cell therapy and other groundbreaking investigations, as well as his thoughts on general developments in oncology and hematology.

Michael Wang, MD, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma.

Michael Wang, MD, discusses how the mantle cell lymphoma paradigm is facing a time of exploration, as researchers examine different therapeutic options beyond chemotherapy.

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses anticipated research in mantle cell lymphoma (MCL).

Simon Rule, MD, discusses a study comparing patients with newly diagnosed mantle cell lymphoma who receive immediate systemic treatment immediately versus patients who are closely monitored instead.